Epidemiology of Prevention of Communicable Diseases
Introduction
Communicable diseases are illnesses caused by viruses or bacteria that people spread to one another through contact with contaminated surfaces, bodily fluids, blood products, insect bites, or the air.[1] There are many examples of communicable diseases, some of which require reporting to appropriate health departments or government agencies in the locality of the outbreak. Some examples of communicable diseases include HIV, hepatitis A, B, and C, measles, salmonella, measles, and blood-borne illnesses. The most common forms of spread include fecal-oral, food, sexual intercourse, insect bites, contact with contaminated fomites, droplets, or skin contact.[2][3][4]
Specifically, hepatitis is a form of a communicable disease that is spread through the oral-fecal route. An individual is exposed to hepatitis by coming in contact with blood products, consuming contaminated water, having sex with another infected person (oral and intercourse), or eating food that is contaminated by the virus. Six criteria need to be met to diagnose a hepatitis infection. These criteria include an infection agent, in this case, the hepatitis virus, a reservoir, route of infection, transmission mode, route of entry, and a susceptible subject who becomes infected with the virus.
Hepatitis A virus (HAV) is a communicable disease preventable through vaccination. It affects the liver, causing jaundice. It is transmitted person-to-person through food consumption, oral sexual contact, poor hand hygiene after using the bathroom or changing diapers, and contaminated water. It is one of the most reported outbreaks in the United States. It is self-limited after ingestion through contaminated food sources. The virus replicates in the liver, is excreted in bile, and can reach high concentrations in the stool.
Stool concentrations are the highest 2 weeks after transmission. Patients are considered non-infectious about a week after inoculation or the onset of jaundice. Patients who are symptomatic most often present with acute onset fever, malaise, jaundice, hepatomegaly, and abdominal pain. Jaundice is often followed by marked elevated serum aminotransferases that are greater than 1000 units/L. The test of choice is IgM anti-hepatitis A virus for diagnostic purposes. There is no specific therapy available. Presently, supportive and conservative management is the mainstay of treatments. Prevention includes personal hygiene or active or passive immunization.[5][6]
Function
Register For Free And Read The Full Article
- Search engine and full access to all medical articles
- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Function
Four major patterns of HAV infections worldwide are divided into areas of high, intermediate, low, or very low prevalence. Endemic areas of high prevalence include parts of Africa, Asia, and Latin America. Most infections in these areas occur in early childhood. Areas of low and very low prevalence include North America and Western Europe, with few infections during childhood, and most of the population is susceptible throughout adulthood.
In the United States, HAV is one of the most reported diseases among vaccine-preventable diseases. Over 30,000 cases were reported in 1997. An estimated 270,000 HAV infections are said to have occurred each year between 1980 and 1999. A total of 1390 cases of hepatitis A were reported from 50 states to the Centers for Disease Control and Prevention (CDC) in 2015. There was a 12.2% increase in reported cases of HAV in 2014. Of note, the overall incidence in 2015 was 0.4 cases per 100,000 population, the same as in 2014 (CDC, 2017). Since 1996, the declining incidence in the United States has been attributed to the widespread use of HAV vaccination for high-risk populations. An incidence of 1 case per 10,000 was notably the lowest recorded in 2007. States with routine vaccination for children also noticeably made the most noticeable difference (Epocrartes, 2017). Overall, there has been a 95% decline in HAV in the United States since the vaccine for HAV became available in 1995.
Globally, HAV's epidemiology is evolving, partly attributed to improved sanitation standards and living conditions, mostly noticeable in developing countries. This has undoubtedly contributed to the decline in infected children globally. However, the incidence among adults has increased due to the larger population lacking antibodies that are protective against HAV.[7][8]
Issues of Concern
Recently, the Division of Disease Control and Health Protection issued a Healthcare Provider Advisory note on HAV in Florida, indicating that 217 cases have been reported in Florida alone since January 2017, a significant increase compared to the past 5-year average of 94 cases. Of note was that most HAV cases did not have international travel exposure. Southeast Florida (eg, Broward and Miami-Dade counties) had the most cases of HAV, with 69% among males (most had male sexual contact). The median age of reported cases was 38 years, with the highest rates of Hepatitis A disease recorded among people ages 25 to 44 years. About 60% of the cases of HAV in Florida required hospitalization.
Also of note is the fact that nearly 1200 outbreaks of HAV were recorded among individuals who are homeless, use intravenous (IV) drugs, men who have sex with men, and their close or direct contacts, as investigated by the health departments in Arizona, California, Colorado, Michigan, New York and Utah (DOH, Florida 2017).
Clinical Significance
History and Physical Examination
- Acute onset fever
- Fatigue
- Malaise
- Nausea and vomiting
- Jaundice
- Hepatomegaly
- Right upper quadrant pain
- Joint pain
- Clay-colored bowel movements
Other Clinical Factors
- Headache
- Fatigue
- Dark urine
- Pruritus
- Rash
- Arthralgias and myalgias
- Cough
- Bradycardia
- Diarrhea
- Constipation
- Splenomegaly
- Posterior cervical lymphadenopathy
Diagnostic Tests
- Serum aminotransferases
- Serum bilirubin
- BUN
- Serum Creatinine
- Prothrombin time
- IgM anti-hepatitis A virus (HAV)
- IgG anti-hepatitis A virus (HAV)
- Stool and body fluid electron microscopy
- Hepatitis A virus RNA
Treatment Options
Presumptive: If unvaccinated with recent exposure to HAV less than 2 weeks: HAV or immune globulin
Acute presentation HAV infection
- Confirmed HAV: Supportive and conservative management
- Worsening jaundice and encephalopathy: liver transplant
Recommendations of the Advisory Committee on Immunization Practices: DOH Florida, 2017.
- All children at age 1 year
- Persons who are at increased risk for infection
- Persons who are at increased risk for complications from HAV
- Any person wishing to obtain immunity
Other Issues
Recommendation for two-dose HAV vaccine, 6 to 12 months apart, for the following persons:
- Men who have sex with men
- Injection and non-injection drug users
- Persons with chronic liver disease
- Persons traveling to or working in countries with high or intermediate endemicity of hepatitis A
- Persons with clotting-factor disorders
- Household members and other close personal contacts of adopted children newly arriving from countries with high or intermediate hepatitis A endemicity
- Persons with direct contact with persons who have hepatitis A
Enhancing Healthcare Team Outcomes
Communicable diseases are illnesses caused by viruses or bacteria that people spread to one another through contact with contaminated surfaces, bodily fluids, blood products, insect bites, or the air. There are many examples of communicable diseases. Health professionals must be aware that some require reporting to appropriate health departments or government agencies in the locality of the outbreak. Some examples of reportable communicable diseases include HIV, hepatitis A, B, and C, measles, salmonella, measles, and blood-borne illnesses. The most common forms of spread include fecal-oral, food, sexual intercourse, insect bites, contact with contaminated fomites, droplets, or skin contact. Improving health professionals' understanding of communicable diseases that must be reported can lead to better patient outcomes.
Nurse educators and infectious disease nurses are crucial in educating clinicians and nurses to avoid spreading communicable diseases in the hospital setting. Further, the infectious disease nurse assists in identifying concerns and reporting issues to the interprofessional team managing a patient's care. Often, this involves more stringent infection prevention precautions and guiding the interprofessional team caring for the patient to avoid further spread of disease and obtain the best outcomes.
References
Wang P, Li Z, Jones A, Bodner ME, Dean E. Discordance between lifestyle-related health behaviors and beliefs of urban mainland Chinese: A questionnaire study with implications for targeting health education. AIMS public health. 2019:6(1):49-66. doi: 10.3934/publichealth.2019.1.49. Epub 2019 Feb 20 [PubMed PMID: 30931342]
Moein D, Masoud D, Mahmood N, Abbas D. Epidemiological Trend of Cutaneous Leishmaniasis in an Endemic Focus Disease During 2009-2016, Central Iran. Turkiye parazitolojii dergisi. 2019 Jun 17:43(2):55-59. doi: 10.4274/tpd.galenos.2019.6064. Epub [PubMed PMID: 31204455]
Level 2 (mid-level) evidenceHeller O, Somerville C, Suggs LS, Lachat S, Piper J, Aya Pastrana N, Correia JC, Miranda JJ, Beran D. The process of prioritization of non-communicable diseases in the global health policy arena. Health policy and planning. 2019 Jun 1:34(5):370-383. doi: 10.1093/heapol/czz043. Epub [PubMed PMID: 31199439]
Zhou S, Davison K, Qin F, Lin KF, Chow BC, Zhao JX. The roles of exercise professionals in the health care system: A comparison between Australia and China. Journal of exercise science and fitness. 2019 Jul:17(3):81-90. doi: 10.1016/j.jesf.2019.04.001. Epub 2019 Apr 21 [PubMed PMID: 31193075]
Level 2 (mid-level) evidenceMcNamara LA, Potts CC, Blain A, Topaz N, Apostol M, Alden NB, Petit S, Farley MM, Harrison LH, Triden L, Muse A, Poissant T, Wang X, MacNeil JR. Invasive Meningococcal Disease due to Nongroupable Neisseria meningitidis-Active Bacterial Core Surveillance Sites, 2011-2016. Open forum infectious diseases. 2019 May:6(5):ofz190. doi: 10.1093/ofid/ofz190. Epub 2019 Apr 15 [PubMed PMID: 31123695]
Guerra CA, Kang SY, Citron DT, Hergott DEB, Perry M, Smith J, Phiri WP, Osá Nfumu JO, Mba Eyono JN, Battle KE, Gibson HS, García GA, Smith DL. Human mobility patterns and malaria importation on Bioko Island. Nature communications. 2019 May 27:10(1):2332. doi: 10.1038/s41467-019-10339-1. Epub 2019 May 27 [PubMed PMID: 31133635]
Phillips JA. Chlamydia Infections. Workplace health & safety. 2019 Jul:67(7):375-376. doi: 10.1177/2165079919853590. Epub 2019 Jun 10 [PubMed PMID: 31179859]
Whitty CJM, Ansah E. Malaria control stalls in high incidence areas. BMJ (Clinical research ed.). 2019 May 21:365():l2216. doi: 10.1136/bmj.l2216. Epub 2019 May 21 [PubMed PMID: 31113780]